Biosight Is A Private Phase 2 Clinical Stage Biotech Company Developing Innovative Therapeutics For Hematological Malignancies And Disordersbiosight S Lead Productbst 236Aspacytarabine Is An Innovative Proprietary Anti Metabolite Which Addresses Unmet Medical Needs By Enabling High Dose Chemotherapy With Reduced Systemic Toxicitybst 236 Is Currently Being Investigated As A Single Agent In A Phase 2B For First Line Treatment Of Acute Myeloid Leukemiaaml Following Completion Of A Phase 1 2A Study Which Demonstrated Tolerability With Promising Efficacy In The Challenging Population Of Aml Patients Unfit For Standard Of Care Chemotherapya Phase 2 Study In Relapsed Refractory Aml And Myelodysplastic Syndromemdswill Be Launched In 2020 Under A Collaboration Agreement Recently Signed With The European Cooperative Groupgfm
